WE Life Sciences
Q4 2024

Wallonie Entreprendre


Wallonie
Entreprendre
Life Sciences

Life Sciences: big success comes from small companies

If COVID-19 has shown us one thing, it's that small companies are the key drivers of innovation in life sciences today.

Wallonie Entreprendre Life Sciences

Wallonia has a unique position within the Life Sciences

Over 180 **small and medium-sized life sciences companies.**

A solid network of **renowned universities** and research institutes.

Strong track record in life sciences, as leading industry players have acquired several Walloon life sciences companies in recent years.

Home to some of **Belgium's most promising startups**, including Aboleris, EsoBiotec, Novadip, Samantree. But also, a hotspot for leading service compagnies such as, IDDI, Ncardia, Quality Assitance, UniD Manufacturing.

Key research, production, and logistic activities of **global companies** like GSK Vaccines, Baxter, Johnson & Johnson, Abbvie, Takeda, UCB, IBA, Zoetis and Catalent.

Wallonie Entreprendre Life Sciences

Life Sciences sector is under pressure

The biotech landscape has become **increasingly intricate since 2021.** After the surge of innovation driven by the COVID-19 pandemic, the sector now faces a series of significant challenges. From the **correction of inflated valuations** and a tougher market for IPOs, to **economic pressures** like inflation and rising production costs, the environment has shifted. Geopolitical tensions, especially the **impact of the Ukraine war** and **US-China trade relations**, have further complicated the global biotech ecosystem.

WE invest in ‘Local Heroes’

Francesca Rapino
COO **THERAtRAME**

Pierre Close
CSO **THERAtRAME**

WE fund life sciences entrepreneurs who leverage their innovation to build a sustainable and equitable global economy **with roots in Wallonia**

Wallonie Entreprendre Life Sciences

What we bring to the table

1. **Long Term Partner**
2. **Empowering Success Through Strategic Network**
3. **Diverse and Committed Team**

Wallonie Entreprendre Life Sciences

1. Long Term Partner

WE are comfortable investing in the most promising very early-stage companies and can act with a long-term view – longer than the average VC.

WE are not afraid to go to places where few people have been before.

2. Empowering Success Through Strategic Network

WE have established a robust network, providing valuable and diverse opportunities for impactful collaborations, sustainable growth, and a long-term success at every stage of development.

Wallonie Entreprendre Life Sciences

3. Diverse and Committed Team

WE are committed to making each of our companies successful.

WE don’t limit ourselves to providing funding and advice to our companies.

WE are known for personally guiding them on the challenging journey of turning innovation into a successful business.

Wallonie Entreprendre Life Sciences

Our Partners

WE are LP in

WE co-invest with

YOU are our future partner

In 2024, we've strengthened our team

We are thrilled to announce the expansion of our Life Sciences team with two outstanding additions!

In November 2023, **Valentin Tonnel** joined us as **Investment Manager**. Valentin combines scientific and financial expertise to support biotechnology and medical device companies. Previously, he supported nearly 40 projects in strategy and funding at a corporate finance firm, driving innovation and growth.

In August 2024, **Julien Maquet** became our **Financial Analyst**. With a master's in Biomedical Data Management and entrepreneurial experience, he strengthens our financial analysis and strategic capabilities.

Welcome to both!

Our Life Sciences Team

Caroline Thielen, PhD

- Investment Manager at WE Life Sciences since 2020.
- Over 20 years of experience in managing and coordinating research projects at both national and internation levels.
- Former Chief Operating Officer at Bridge2Health (B2H), where she played a key role in advancing the healthcare ecosystem in Liège.
- Holds a Master's degree in Biology and a PhD in Immunology from the University of Liège.
- Postdoctoral training at the CDC in Atlanta, USA.

Christina Franssen, PhD

- Investment Manager at WE Life Sciences since 2019.
- Over 20 years of experience in innovation and research.
- Previously held roles as Director and BD Manager of state-of-the-art technology platforms at GIGA (CHU/ULiège).
- Founder and CEO of DNAVision AgriFood, a spin-off of University of Liège (full cycle of entrepreneurship from founding to exit).
- Started her career as a research scientist at the University of Liège.
- She holds a Ph.D in Microbiology & Genetics and a Master's degree in biology from the University of Liège.

Gery Lefebvre, MBA

- Investment Manager at WE Life Sciences since 2014.
- Nearly 30 years of experience in management and finance, with both national and international exposure across various sectors, including banking, chemicals and pharmaceuticals.
- He holds several non-executive positions in biotech/medtech start-ups, as well as in CROs and CDMOs.
- Before his current role at WE, He was notably responsible for Treasury Management and Working Capital Optimization at GSK Biologicals.
- His academic credentials include a Master in Business Administration and a Master in Taxation from HEC-Uliège.

Sophie Sauvage, MBA

- Investment Manager at WE Life Sciences since 2020.
- She has extensive experience in corporate finance, including roles in auditing and M&A in Luxembourg.
- She is passionate about the medical sector and holds board mandates in various companies, from startups to SMEs.
- Driving strategic growth and innovation through her board roles.
- Holds a degree in business administration from HEC- ULiège.

Valentin Tonnel, MSc

- Investment Manager at WE Life Sciences since 2023.
- Prior to WE, Valentin was a Financial Advisor at a small corporate finance firm in Belgium, where he managed around 40 projects in strategic planning and funding.
- Uses his dual expertise in Science and Finance to support innovative companies in biotechnology and medical devices as a board member.
- Holds a Master's degree in Molecular Biology and Genetics from the University of Louvain.
- Professional certificate in Healthcare Finance from MIT.

Julien Maquet, MSc

- Financial Analyst at WE Life Sciences since 2024.
- In 2019, he launched a company, which he successfully sold in 2023, showing his entrepreneur initiative.
- His thesis involved developing a complex financial model for innovative treatments.
- During his internship in a CFO part time company, he assisted biotech startups with financial planning, sales strategy and market analysis.
- Graduated in Biomedical Sciences establishing a solid foundation in scientific and medical fields.
- Completed a Master's degree in Biomedical Data Management, enhancing skills in analysis, statistics, programming and database creation.

Wallonie Entreprendre Life Sciences

Our Team
Caroline Thielen, PhD

Investment Manager
caroline.thielen@wallonie-entreprendre.be | +32 498 70 62 22

Current portfolio

ABOLERIS PHARMA
THE IMMUNE SYSTEM UNDER CONTROL

atb therapeutics

Dendrogenix

epics THERAPEUTICS

ExeVir

EyeD Pharma
Delivery of VISION CARE

iSTAR MEDICAL

KiOmed PHARMA

PDC*line pharma
ADVANCED CANCER VACCINES

UniD Manufacturing
Your INDUSTRIAL PARTNER for drug release in micro dimensions

Wallonie Entreprendre Life Sciences

Our Team
Christina Franssen, PhD

Investment Manager
christina.franssen@wallonie-entreprendre.be | +32 474 39 73 99

Current portfolio

EsoBiotec
NeuVasQ BIOTECHNOLOGIES
NOVADIP
PANTERA
Santero Therapeutics
Synergia Medical
THERAMETRAME Discover new therapies
Univercells Biologics for all

Wallonie Entreprendre Life Sciences

Our Team
Gery Lefebvre, MBA

Investment Manager
gery.lefebvre@wallonie-entreprendre.be | +32 496 21 13 40

Current portfolio

BePharBel Manufacturing
bloomlife
iba
iTEOS THERAPEUTICS
KitoZyme Our technologies for Health Your success !
minoryx therapeutics
Nyxoah
OncoDNA THE CANCER THERANOSTIC COMPANY
QUALITY ASSISTANCE Contract Research Organisation

Wallonie Entreprendre Life Sciences

Our Team
Sophie Sauvage, MBA

Investment Manager
sophie.sauvage@wallonie-entreprendre.be | +32 473 82 30 94

Current portfolio

aSEPTIC TECHNOLOGIES

AXINESIS ADVANCING REHABILITATION

CERHUM

cognivia

gabi SMARTCARE

LiveDrop

MYOCENE

neuroClues

PLAST4LIFE

Secoya FLUIDIFY PHARMA

The Akkermansia Company

Wallonie Entreprendre Life Sciences

Our Team
Valentin Tonnel, MSc

Investment Manager
valentin.tonnel@wallonie-entreprendre.be | +32 471 51 37 16

Current portfolio

ABSCINT Molecular Imaging

axithra

SamanTree Technologies

Wishbone

Wallonie Entreprendre Life Sciences

Our Team
Julien Maquet, MSc

Financial Analyst
julien.maquet@wallonie-entreprendre.be | +32 479 20 09 23

Enhance the team by driving value added contribution :

- Financial Data Analysis
- Scientific Data Analysis
- Stastistical Analysis
- Market Analysis
- Report and Presentation
- Strategic Advisory

Newsflow, H1 2024

February

Myocène muscle tech takes the stage! The company secures medical ISO certification for the US, eyeing huge opportunities in elite sports across the Atlantic while already powering top European clubs like PSG and OGC Nice.

April

Through our **investments** in the **LSP6** and **Fund+ funds**, we indirectly benefited from to two major acquisitions: AstraZeneca's record $1 billion purchase of **Amolyt Pharma** and Novo Nordisk's €1 billion acquisition of **Cardior Pharmaceuticals**, marking great exits for our portfolio.

Cognivia has raised **€15,5M** in strategic funding to optimize and accelerate drug development programmes through AI-ML solutions.

May

Astellas, which acquired **Ogeda**, received **FDA approval for Ogeda's GPCR-targeting** product for hot flashes in women, paving the way for its market launch in the USA. This achievement represents **€31M** in gains for WE, in a total return of €200M.

In May, **WE Life Sciences** was also proud to have committed **€5M** to the **Kurma Partners fund**. We are delighted to count Kurma Partners as one of our partners.

June

Swedish giant **EQT** acquires Walloon clinical trial leader **CluePoints** in a record transaction valued at over half a billion euros. WE Life Sciences has exited its investment in CluePoints, realizing a capital gain of **€61M**.

Newsflow, H2 2024

August

Esobiotec raises an additional **€6M** in its Seed round, with InVivo Capital joining the existing syndicate of Thuja Capital, UCB-Ventures, SI, and WE Life Sciences. This funding will enable Esobiotec to advance to the clinic with its first off-the-shelf *in vivo* CAR-T product.

September

We proudly participated in SamanTree Medical SA's **€12.5M Series B round**. Specializing in advanced medical imaging, this medtech has secured FDA approval to market its revolutionary Histolog Scanner in the US.

November

PanTera secures **€95.6M** in the largest-ever Series A round, paving the way for groundbreaking cancer treatments with Actinium-225 production.

ATB Therapeutics has secured a record-breaking **€54M** in Series A funding, marking the largest in Wallonia, This funding will propel the development of ATB's ATBioFarm platform.

Wallonie Entreprendre Life Sciences

#chooselife

About WE Life Sciences

64

Active Portfolio Companies
at the end of Q4 24

15

Exits
at the end of Q4 24

214M€

Total assets (AUM)
at the end of Q4 24

315M€

Cumulative ROI
at the end of Q4 24

Wallonie Entreprendre Life Sciences

About WE Life Sciences

ACTIVITY TYPES



ASSET CLASSES



INDICATIONS



Wallonie Entreprendre Life Sciences

Our Investments, Your Health

From Lab to Lives

55
Medicines discovered or in development phases

3500
Patients enrolled

15
Indications targeted

Innovation

6
First-in-class

7
Best-in-class

Shaping the Future

5
Discoveries

19
Pre-clinical

17
Phase 1

12
Phase 2

4
Phase 3

Impact

>500M
Patients could benefit from

13
Marketed Products

Wallonie Entreprendre Life Sciences

Biopharma Portfolio

Wallonie Entreprendre Life Sciences

In Our Portfolio

ABOLERIS PHARMA
THE IMMUNE SYSTEM UNDER CONTROL

www. aboleris-pharma.com

Corporate

HQ : Gosselies, Belgium
Funds raised : 32.3M€ capital
Management team : Ann Meulemans CEO, Tomas Van Dyck CFO, Ronald Van Brempt CMO, Carole Guillonneau Head of Research, Benoit Moreaux Head of Operations

Technology

AbolerIS' lead compound anti-CD45RC antibody (ABO21009) has a novel and unique mechanism of action with capacity to deplete pathogenic lymphocytes and preserve regulatory and memory T cells (rebalancing Teff/Treg ratio).

Business

AbolerIS Pharma is developing a **first-in-class monoclonal antibody** for inflammatory & autoimmune diseases, inducing immune tolerance and preserve useful immune responses.

Milestones

- AbolerIS Pharma finalized a successful series A financing of 27,3M€ on September 17th, 2023.
- AbolerIS Pharma opened new office in BioPark of Gosselies in October 2023.
- AbolerIS targets First in Human for ABO21009 by Q3-Q4 2024, and validation in patients with Rheumatoid Arthritis by 2026 onwards.
- CTA filing Dec 24
- FIH Feb 2025

Wallonie Entreprendre Life Sciences

In Our Portfolio

https://www.atbtherapeutics.com/

Corporate

HQ : Marche-en-Famenne, Belgium
Funds raised : 60M€ capital
Management team : Mark Throsby Executive Chair & CSO, Bertrand Magy CEO,
Max Houry COO, Philippe Vandeput CBO

Technology

The ATBioFarm technology facilitates the scalable, single-step production of these sophisticated, highly stable and homogenous biologics, promising significant advancements across various therapeutic applications.

Business

ATB Therapeutics is dedicated to pioneering First-in-Class biologics that incorporate novel cell killing mechanisms, including enzymatic functionalities within targeted antibodies.

Milestones

- ATB Therapeutics SA secured a series A financing of 54M€ on November 18th, 2024.
- Proceeds will fund clinical development of oncology as well as immunology therapeutics derived from ATB's innovative platform
- Mark Throsby, industry veteran and former CSO of Merus, joins as Executive Chair

Wallonie Entreprendre Life Sciences

In Our Portfolio

Dendrogenix
www. dendrogenix.com

Corporate

- **HQ :** Liège, Belgium
- **Funds raised :** 24M€ Serie A including 7M€ non-dilutive
- **FTE :** 20 employees
- **Management team :** Jean COMBALBERT, Chairman, Stéphane SILVENTE CEO, Philippe LEFEBVRE CSO, Pierre ATTALI CMO, Nicolas CARON CDO

Business

DENDROGENIX is a biopharmaceutical company based in Liège dedicated to developing NCE (New Chemical Entities) **named "Dendrogenins"** till early clinical development to address important unmet medical needs in the field of **neurological disorders** with a first therapeutic indication on hearing loss, and more specifically in presbycusis indication.
The presbycusis market segment represents a real opportunity as the first targeted pathology. It is an excellent therapeutic indication to illustrate the potential of DX243 in all diseases where synapses uncoupling is involved.

Technology

Dendrogenins are cholesterol derivatives and are powerful **inducers of cell differentiation**. These drugs are well indicated for multiple pathologies due to **neuronal impairment. DX243** lead compound is evaluated in a phase I-II clinical study in the field of **sensorineural hearing loss** and more specifically on presbycusis indication. A second indication foreseen for the Dendrogenins is, acting as neuroprotectant, in ischemic stroke condition & traumatic brain injury (TBI).

Milestones

2018/2019 :
- Assets acquisition from Affichem & Inserm (FR)
- Non-dilutive funding granted by SPW EER
- Implementation of the Drug discovery & Development platform
- Noshaq investment

2020/2021 :
- Scale-up and manufacturing of a GMP batch of DX243
- Fund-raising from Med-El & non-dilutive funding from SPW EER

2022 :
- Regulatory toxicology package of DX243
- Fund-raising from Noshaq, WE & Med-El
- Non-dilutive funding from SPW EER

2023/2024 :
- Phase I-II in hearing loss indication
- Fund-raising from Noshaq, WE & Med-El
- Non-dilutive funding from SPW EER

Wallonie Entreprendre Life Sciences

In Our Portfolio

www. epicstherapeutics.com

Corporate

HQ : Gosselies, Belgium
Funds raised : ~€30M€ capital
Management team : Graeme Fraser CEO

Technology

EPICS has a pipeline of proprietary, best-in-class products developed against novel targets with unique mode of actions to treat types of cancer where there is a still a critical, unmet medical need.

Business

EPICS is a clinical stage company working in the field of RNA epigenetics and immunotherapy to develop novel therapeutics in oncology.

Milestones

- EP102 is a best-in-class inhibitor of METTL3 with robust activity in disease models of solid tumors and hematological cancers. EP102 will enter clinical testing in patients in Q1 2025
- EP282 is a first-in-class FFAR2 agonist poised to enter phase 2 clinical testing in autoimmune diseases
- EP609 is a first-in-class program on a GPCR target with breakthrough potential in cancer immunotherapy

In Our Portfolio

Info@esobiotec.com

Corporate

HQ : Gosselies, Belgium.
Funds raised : over 9M€
Cash runway into 2024.
Management team : Jean-Pierre Latere CEO, Philippe Parone VP of R&D.

Technology

ENaBL platform for *in vivo* engineering of cells for production of cell therapies for both hematological malignancies and solid tumors.

ENaBL is a disruptive proprietary technology that allows manufacture of cost effective off-the-shelf products for cancer patients.

Business

In vivo production of CAR-T and TCR-T products to treat various cancers.

Milestones

Preclinical proof of concept and pre-GMP manufacturing in 2022/2023.

In Our Portfolio

www.exevir.com

Corporate

HQ : Liège, Belgium
Funds raised : 42M€ Series A financing and 18M€ in non-dilutive funding
Management team : Jeanne Bolger interim-CEO, Viki Bockstal CSO, Caroline Sagaert COO

Technology

Modular platform technology uses camelid heavy chain-only antibody fragments (VHH) fused to a human IgG Fc. The modular VHH building blocks provide a unique combinatory flexibility. VHHs have the potential to access unique and occluded epitopes that are often highly conserved and more difficult, if not impossible, to access for conventional monoclonal antibodies. VHH-Fc constructs are very stable, easy to produce and cost-effective.

Business

Pioneering the future of antibody therapies in infectious diseases:

- COVID-19: XVR013m a variant-proof and broad – spectrum long-acting antibody targeting a highly conserved epitope in the S2 subunit of the spike protein to protect and treat immunocompromised and elderly.
- Dengue: Innovative prevent and treat strategy addressing a rapidly growing health problem.
- Pandemic preparedness

Milestones

- Manufacturability and safety in COVID-19 infected patients established, team capabilities validated by prior development compound, XVR-011.
- New Development candidate, XVR013m plans discussed with international regulatory authorities to support CMC and FIH in 2025.

In Our Portfolio

www.iteostherapeutics.com

Corporate

HQ : Watertown, MA, USA + R&D in Gosselies, Belgium

Funds raised : 714M€ capital with runway through 2027

Listed on NASDAQ: ITOS

Management team : M.Detheux CEO, D.Feltquate, CMO, M.Call COO, M.Gall CFO, Y.McGrath CSO.

Business

- GSK collaboration focused on belrestotug (TIGIT) program where iTeos received $625MM upfront and $1.45B in potential milestone payments.
- iTeos and GSK are advancing various TIGIT + PD-1 and novel combinations in multiple trials, including a registrational Phase 3 trial in PD-L1 high 1L NSCLC.
- Evaluation of best-in-class A2AR small molecule, inupadenant, in 2L NSCLC in combination with chemotherapy.
- Developing an innovative pipeline with intra-portfolio synergies to accelerate and expand clinical development of our targets.
- ~$714MM cash balance as of Q2'24 providing a runway through to 2027.

Technology

iTeos Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients. The Company's innovative pipeline includes three clinical-stage programs targeting immunosuppressive pathways designed with optimized pharmacologic properties for improved clinical outcomes, including the TIGIT/CD226 axis and the adenosine pathway. iTeos Therapeutics is headquartered in Watertown, MA with a research center in Gosselies, Belgium.

Milestones

- Proffered paper on Phase 2 GALAXIES Lung-201 at ESMO 2024 demonstrating the strongest TIGIT+PD-1 dataset in PD-L1 high 1L NSCLC ever, with 60% cORR at every TIGIT+PD-1 dose.
- Longer-term follow up data from Phase 2 GALAXIES Lung-201 including PFS and additional ORR, safety, and ctDNA data anticipated in 2025.
- iTeos and GSK initiated a registrational Phase 3 trial in PD-L1 high 1L NSCLC patients with the combination of belrestotug and dostarlimab (GSK PD-1) in June 2024.
- iTeos anticipates adenosine pathway data before YE24 from Phase 2 A2A-005 (inupadenant + chemotherapy) and Phase 1 APT-008 (EOS-984).

In Our Portfolio

KitoZyme
Our technologies for Health
Your success !

www.kitozyme.com

Corporate

HQ : Liège, Belgium
Funds raised : 35M€

Technology

BioTech - Bio-polymers:
- Chitosan
- Chitin-glucan

World leader fungal chitosan
Patents & Innovation

Business

1. Health Care
- Digestive Health
- Weight Management
- Cardiovascular

2. Agriculture
- Wine
- Plant

Milestones

2000-2012 : R&D
2014 : Spin-out of
KiOmed Pharma – Biomedical applications
2015 : Financial Break-even
2016 : Net profit
2011-2019 : Sales growth of + 34% per annum

Wallonie Entreprendre Life Sciences

In Our Portfolio

www.minoryx.com

Corporate

HQ : Charleroi, Belgium

Funds Raised : 120M€

FTE : 29 employees with operations in Belgium (Brussels South Biopark) and Spain (Barcelona)

Management team : Marc Martinell CEO, Arun Mistry CMO, Hans Christian Keller CBO

Technology

Lead candidate: leriglitazone (PPAR gamma agonist)

Preparing for MAA in EU for cALD upon finalization of ongoing study in paediatric patients.

In the US, ongoing Phase 3 in adult patients

Proof of concept study completed for Friedreich's Ataxia

Orphan Drug Designation granted for X-ALD (EU & US)

License agreement with Neuraxpharm for the European rights to leriglitazone, and Sperogenix for the Chinese rights

Business

First to market opportunity in cerebral ALD (cALD). Most advanced drug candidate worldwide targeting this lethal form in both paediatric and adult population

Indication expansion to other orphan CNS diseases

Milestones

Final results pediatric study by early 2025, leading to MAA in EU

Complete recruitment of FDA-agreed Ph3 study in 2025

Aiming to become a worldwide leader in X-ALD and other orphan CNS diseases

In Our Portfolio

Ncardia
Stem cell experts

cellistic

www.ncardia.com

Corporate

HQ : Mont-Saint-Guibert
Funds raised : 60M€
FTE : Currently 60+ employees, continuous expansion
Management team : Gustavo Mahler CEO, Stefan Braam CTO, Jonas Mortensen CCO, Charles Jacques CFO

Business

Ncardia:
Ncardia provides specialized screening and analytical services using iPSC derived human tissues *in vitro* to derive novel insights for gene therapy, biologic and small molecule drug candidates. By bringing specific human biology into the lab, we help therapeutic developers to get complex therapies get to market faster, by performing novel analyses *in vitro*, that greatly enhance the probability of *in vivo* success.

Cellistic :
Cellistic is building world-class robust and scalable allogeneic iPSC-based immune cell therapy development and manufacturing platforms that enable cell therapies to achieve their full potential in improving human health.

Technology

Area of interest: applications of stem cell derived cells in drug discovery and cell therapy
Services description:

- **Ncardia:** Drug discovery services using Ncardia healthy and diseased cellular models
- **Cellistic:** IPSC cell therapy contract development and manufacturing services

Milestones

- Launch of Cellistic in April 2022
- Cellistic announces partnership with Quell therapeutics for the development of iPSC Treg therapeutics in May 2022

Wallonie Entreprendre Life Sciences

In Our Portfolio

Corporate

- **HQ :** Ottignies-Louvain-la-Neuve, Belgium
- **Funds raised :** 1.5M€ Seed funding + non-dilutive 3.6M€, Series A in June 2023 (non-disclosed)
- **Management team :** Thierry Hercend Executive Chairman, Didier Le Normand CEO, Stefano Crosignani VP R&D

Technology

In vitro and *in vivo* cancer models
Medicinal chemistry

Business

Immunostimulatory ADCs for cancer therapy

Milestones

Preclinical proof of concept Q1 2025

In Our Portfolio

www.neuvasq.com

Corporate

HQ : Gosselies, Belgium
Funds raised : 20M€ Series A
Management team : Emmanuel Lacroix CEO, Ralph Laufer CSO

Technology

Wnt pathway activators that leverage innovative targets, Gpr124 and Reck, to restore the integrity of the blood-retinal barrier and ameliorate vision in patients with Diabetic Macular Edema and wet Age-related Macular Degeneration. Other programs in Neurology.

Business

Neuvasq Biotechnologies is focusing on the discovery and development of pioneering therapies that restore CNS barriers to improve patients' vision and neurological functions

Milestones

Neuvasq engineered series of Wnt surrogate antibodies with efficacy *in vitro* (e.g. selective Wnt pathway activation in brain and retinal endothelial cells) and *in vivo* (mouse model of retinal vascular lesions). Lead optimization ongoing with non-clinical development to start in 2025.

In Our Portfolio

NOVADIP

www.novadip.com

Corporate

HQ : Mont-Saint-Guibert, Belgium
Funds raised : 117M€ including equity and non-dilutive
FTE : 50 employees
Management team : Denis Dufrane CEO & Scientific Founder, Judy Ashworth CMO, Eric-Paul Pâques Board's Chairman

Business

Develop a **new class of regenerative tissue products** that accelerate healing of large bone defects, bone non-union and spine fusion **in a single treatment**

Technology

2 main categories of products for bone reconstruction

- **Autologous**: **First in Class**

Autologous product for large bone reconstruction to avoid amputation

- **Off-The-Shelf: Best in Class**

Allogeneic product with biological properties for common orthopedic conditions to position as a key competitor in the Graft Bone Substitute market

A **discovery program for Cell-free Exosome/Matrisome** targeting oncology (tumor regression) and rejuvenation

Milestones

60+ patients already treated

Autologous : Two clinical trials fully enrolled (EU + US)
- Clinical trial in adults with bone non-union - completed (EU)
- FDA pilot trial in a rare and pediatric indication fully enrolled (US+EU)
- FDA pivotal trial in preparation

Off-the-shelf: Two clinical trials fully enrolled (EU)
- One in spine fusion and one in trauma (radius)
- FDA spine fusion trial planned for 2025

In Our Portfolio

PDC*line pharma
ADVANCED CANCER VACCINES
www.pdc-line-pharma.com

Corporate

HQ : Liège, Belgium
Funds raised : 62M€, last round led by the Asian leading VC Korean Investment Partners (KIP)
FTE : 42 employees
Management team : Eric Halioua CEO, Laurent Levy CFO, Joel Plumas CSO

Business

Deals

Licensing deal signed with LG-Chem, for the development and commercialization of PDC*lung for lung cancer in Asia. Total deal value is 123M$ plus significant tiered royalties on net sales.

Markets

PDC*line platform can be used for the treatment of virtually all cancer patients expressing HLA-A2 – with extension possibilities to other HLAs.
PDC*lung for advanced non-small cell lung cancer: 584,000 new lung cancer patients with HLA-A2 pheno-type per year, leading cause of cancer deaths, and potential sales of about €3.1B in the peak year

Technology

Platform

New class of potent and off-the-shelf therapeutic cancer vaccines based on a proprietary cell line of Plasmacytoid Dendritic Cells (PDC*line)

Milestones reached

- November 2021: closing of a 17.5M€ B2-Round of financing led by the multi-billion Asian VC, Korea Investment Partners (B1-Round of 20M€ was closed in December 2019, also led by KIP).
- Phase I/II trial in lung cancer in France, Belgium, Netherland, Poland and Germany on 70 patients. **Preliminary results with PDC*lung01 in monotherapy and at high dose with pembrolizumab evoke acceptable safety profile, immunological activity and promising tumor response in Non-Small Cell Lung Cancer.**
- June 2023: relocation of the headquarter in a brand-new facility in Liège (Belgium) including a 330m2 GMP manufacturing Unit.
- January 2024: 8.1M€ grant from the Walloon region to develop PDC*neo for colorectal cancer.

Milestones

Clinical study report for phase I/II clinical trial with PDC*lung by 2024
US and Asia lung cancer study initiation in 2025/2026.
Initiation of trial with neoantigens based vaccines (PDC*Neo) in Q1 2026.
Complete new round of financing in 2025.
Seeking collaborations with biopharma companies.

Wallonie Entreprendre Life Sciences

In Our Portfolio

https://www.santero.be/

Corporate

HQ : Charleroi, Belgium
Funds raised : 12M€ in equity and non-dilutive financing
FTE : 16 employees
Management team : Cédric Govaerts Managing Director & Scientific Founder, Abel Garcia Pino Managing Director & Scientific Founder, Carole Monterrat CFO

Technology

The technology uses a completely new mode of action targeting an enzyme ubiquitously expressed in prokaryotic cells. Santero's ambition is to validate new chemical entities for several pathogens for which a major clinical need is established.

- Primary Target is *Staphyloccocus aureus*
- A second program is ongoing targeting Gram- pathogens

Business

Santero Therapeutics develops a discovering platform of First-In-Class antibiotics to fight against bioresistance.

Milestones

- Hit Series defined for *S. aureus* : End 2023
- Next Milestone: Preclinical PoC and Lead defined for *S. aureus*

In Our Portfolio

THERAtRAME
www.theratrame.com

Corporate

HQ : Liège, Belgium
Funds raised : 2.5M€ Seed funding + 2M€ non-dilutive
Management team : Jonathan Ward CEO, Francesca Rapino COO & co-founder, Pierre Close CSO & co-founder

Technology

Objective: THERAtRAME are pioneering tRNA modulators, **a new class of therapeutics** that **eradicate cancer** acting on the **cancer dependence** on the protein expression machinery to disrupt cancer rapid growth, metastasis, and immune evasion.

Technology: Developing first-in-class tRNA-Modulators targeting tRNA-modifying enzymes.

Business

Identification and validation of a number of novel targets, at different stages of development. Our lead clinical candidate, TTR-001, is currently being developed for melanoma, with proof-of-concept studies underway across several other cancer types.

All our drug candidates are developed based on our proprietary AI-based drug discovery platform (EpiFind™), which allows us to discover inhibitors of tRNA-modifying enzymes and identify the best disease applications.

Milestones

R&D:
1/Completed target validation and hits-to-Lead for target#1 (currently in Lead optimisation)
2/ PoC of THERAtRAME's discovery platform

Business:
Initiate partnership with relevant pharma companies and investors
Identify clinical indications and back-up strategy for further development

Corporate objectives:
Build a dynamic team to develop the DD programs
Build an international governance strategy and partnerships with leading global players in oncology

Wallonie Entreprendre Life Sciences

In Our Portfolio

The Akkermansia Company™

www.theakkermansiacompany.com

Corporate

HQ : Mont-Saint-Guibert, Belgium
Funds raised : 31M€
Management team : Michael Oredsson CEO,
Prof. Willem de Vos & Prof. Patrice Cani Co-Founders

Technology

Food supplements based on a next generation bacteria: **akkermansia muciniphila**

Products launched covering a) metabolic syndrome and b) gut support with stress management

Business

Microbiome based food supplement products

Milestones

2019 : First in **human clinical trial** on metabolic syndrome published in Nature Medicine
2021 : First time a **« Novel Food »** label is granted by the European Union for a next Products launched covering a) metabolic syndrome and b) gut support with stress management
generation bacteria; EU market authorization; US market authorization
2022 : commercial launch in Europe
2023 : additional **funding**; commercial **expansion** (in geographies and in product range); further **human data** generation
2024 : 20 mio eur raised through EIB

Wallonie Entreprendre Life Sciences

Medical technology Portfolio

Wallonie Entreprendre Life Sciences

In Our Portfolio

EyeD Pharma
Delivery of VISION CARE
www. eyedpharma.com

Corporate

HQ : Liège, Belgium
Funds raised : 113.2M€
FTE : 45 employees
Management team : Mélanie Mestdagt CEO & Co-Founder, Marc Foidart Executive Chairman & Co-Founder

Business

Micro-Implants for the Future of Eye Care

Founded in 2012, EyeD Pharma is a clinical stage pharmaceutical company dedicated to **improving the life of patients suffering from ophthalmic diseases** with unmet medical needs such as glaucoma or dry eye.

We develop **innovative therapeutic solutions** based on **sustained release polymeric micro-implants** and inserts. Our leading clinical-stage product candidate is an intraocular implant allowing a sustained release of API up to 9 years that could ensure 100% patient's compliance and could considerably reduce treatment side effects, preventing further vision loss and drastically improving the patient's daily quality of life.

Today, our team gathers experts and managers with an average of 18 years' pharmaceutical expertise in our environment-friendly offices and CDMO in the Science Park of Liège, Belgium.

Technology

- Specialise in the development and production of ocular micro-implants
- **Innovative healthcare products** from unmet needs

Milestones

2017 :
- AFMPS agreement as distributor – Starting distribution business
- **Final prototype** for glaucoma implant

2018 – 2019 :
- **Bausch and Lomb exclusive distribution** in Be-Lux
- Preliminary proof of concept animal for glaucoma implant
- Capital increase
- Own industrial process development, internalisation

2021 :
- Fund-raising, new public grants and capital increase
- **CTA submission**

2022 :
- Inauguration of **new office and CDMO**
- TimoD **Clinical Phase 1 on patients**
- **GMP** agreement for the CDMO

Wallonie Entreprendre Life Sciences

In Our Portfolio

www. cerhum.com

Corporate

HQ : Liège, Belgium
Funds raised : 1.9M€
FTE : 9 employees
Management team : André Claes CEO, Grégory Nolens CSO, Thibaut Breuls de Tiecken CFO

Technology

- **MyBone®** - 3D advanced bone graft solution for faster bone reconstruction (patented), with two EU commercialized products:
  - **MyBone® Custom**: Patient specific bone graft
  - **MyBone® CDMO**: Custom production as a subcontractor
- Medical 3D printing platform, ISO13485-2016 certified

Business

CERHUM is the leader in 3D printing synthetic bone graft.

- Superior solution in bone reconstruction with **MyBone®**
- Active in Maxillofacial, Plastic, Orthopedic and Spine surgery
- Commercially represented in five EU countries
- >10,000 bone graft/year production capacity

Milestones

Two years plan (2022-2024)

- Five folds increased number of sales with **MyBone® Custom**
- Triple the number of industrial partnership with **MyBone® CDMO**
- Double the number of Clinical partners to improve MyBone
- Obtain our first **FDA approval** (US market)
- Validate **MyBone®** to be used in intraoral and oncology indications.

In Our Portfolio

www.istar-medical.com

Corporate

HQ : Wavre, Belgium.

Funds raised : Series A,B,C in 2013, 2016, 2019. Total raised ~115M€*. Convertible loan of ~27M€ in 2024

FTE : 60+ employees

Management team : Michel Vanbrabant CEO, Richard Beckman CMO, Kristine Curtiss VP Clinical Affairs

Technology

Implants to treat Glaucoma
with innovative, soft, flexible, anti-fibrotic STAR® material, made of biocompatible, medical-grade silicone, which enables bio-integration of surrounding tissues into the material.

MINIject® micro-invasive glaucoma surgery (MIGS) device designed to reduce pressure in front of eye caused by fluid build-up, in order to prevent damage to optic nerve. It does this by redirecting excess fluid to a natural drainage pathway (supraciliary outflow).

Business

Objective to be a best-in-class MIGS device for treatment of Glaucoma.

Strategic Alliance with AbbVie AbbVie will hold the exclusive right to acquire iSTAR Medical with additional contingent payments of up to $475M.

Clinical Results STAR-I, II, III, IV Meta-Analysis (n=83) @ 2Y for MINIject® show ~40% sustained reduction of pressure, with ~40 % patients free of pressure-lowering medication.

CE Mark Obtained Q4 2021. Commercial launch in select EU countries

FDA approval US IDE study granted approval by FDA to begin in 2021

Milestones

Accomplished:

- CE-Mark approval
- EU Commercial Launch
- US IDE approval by FDA
- Strategic Alliance with AbbVie
- Commercial Launch in non-EU territories as from 2023

Expected

- US Commercial Launch expected in 2027/2028

In Our Portfolio

www.kiomedpharma.com

Corporate

HQ : Liège, Belgium
Funds raised : 25M€
FTE : 40+ employees
Management team : Houtaï Choumane CEO, François Blondel Founder & Executive Chairman

Business

Target market
Osteoarthritis, Aesthetic medicine, and **ophthalmology** representing >20B $

Product on the market
KiOmedine®^{Vs}One, a unique single-injection fluid implant for knee osteoarthritis

Products in development
A pipeline of 4 products in aesthetic medicine, 2 products in ophthalmology

Technology

Unique position in ultrapure animal-free chitosan polymer:
the KiOmedine®
Area of interest: Regenerative medicine (Osteoarthritis, Aesthetic medicine, and ophthalmology)
Products **description**
Class III injectable implants

Milestones

GLOBAL TARGET : achieve leadership position on our markets in Europe and Asia as of 2026

Major Partnership signed in 09/22 with Hansoh Pharmaceuticals for the distribution of KiOmedine®^{Vs}One in China, initiation of the registration trial.

Osteoarthritis
- ✓ Further grow Europe and Asia market presence of KiOmedine®^{Vs}One
- ✓ Launch in China and Brazil in partnership
- ✓ Launch of new range of innovative solutions

Aesthetic medicine
- ✓ CE Mark of our skin booster (‘25)
- ✓ CE mark of our range of 3 dermal fillers (‘26-’27)

Ophthalmology
- ✓ Development of eye drops for dry eyes

Wallonie Entreprendre Life Sciences

In Our Portfolio

https://nyxoah.com/fr

Corporate

HQ : Mont-Saint-Guibert, Belgium

Funds raised : Dual listing on EURONEXT Brussels and NASDAQ

- 85M€ (100M$) IPO on Euronext in Sept. 2020
- 97.8M$ IPO on NASDAQ in July 2021

Management team : Olivier Taelman CEO, Loïc Moreau CFO

Technology

Medical technology focusing on Obstructive Sleep Apnea (OSA) therapy – the most common sleep disordered breathing condition

First and only leadless, battery-free bilateral neurostimulator – Single incision procedure and patient-centric solution

1.5T and 3T full-body MRI compatibility

Business

1 Billion OSA sufferers worldwide

Target population: patients with moderate to severe OSA who have failed conventional PAP therapy

1M+ new eligible patients every year (500K in the US – 500K+ in Europe)

€20 Billion annual total addressable market

Milestones

CE Mark in 2019

- Germany reimbursement and commercialization since 2020
- Switzerland funding and commercialization since 2021

Completion of BETTER SLEEP study leading to +30% therapeutic indications extension in Europe, unique to Nyxoah

Ongoing US IDE pivotal DREAM study for FDA approval

Ongoing ACCCESS IDE study for FDA CCC labelling expansion

Next Generation Genio 2.1 CE mark approved in Europe + FDA approved as part of ongoing DREAM and ACCCESS IDE studies

In Our Portfolio

Synergia Medical

www.synergia-medical.com

Corporate

HQ : Mont-Saint-Guibert, Belgium

Funds raised : 16.8M€ in Series A, 12.8M€ in Series B and 5M€ non-dilutive

Management team : A. Borbath CEO, Dan Scherrer COO, Dimitri Crelot CFO, Anne Renaud VP Business Development, Vincent de Rudder VP Regulatory.

Technology

First medical device company worldwide developing an optoelectronics neurostimulator.

This neurostimulator sends monochromatic light from an implanted rechargeable pulse generator, via optical fibres, to a photovoltaic cell implanted nearby the target site where light is transformed into electrical pulses.

Metal-free casing & lead: can be used in MRI and hosts physiological parameters sensors for fine-tuning neurostimulation modulation.

Business

First market target: drug-resistant epilepsy, 3M patients in EU and US not properly treated by anti-epileptic drugs.

Many other applications can benefit from the technology: depression, migraine, Parkinson's disease, sleep apnea, etc.

Strong research project financed by the Walloon Region and aiming at improving quality of life for the patients.

Regulatory and market access: Europe and the USA

Milestones

2022 : GLP preclinical study

2023 : V&V testing and manufacturing for pilot clinical study (FiH)

2024 : submission and approval to perform FiH in 3 European centers (5 patients implanted and stimulated)

2025 : Series B2 (EUR 17.5M) + optimisation of manufacturing process for pivotal clinical study

2027 : start US and European pivotal clinical study

2029 : CE mark and FDA approval

In Our Portfolio

Wishbone

www.wishbone-biotech.com

Corporate

HQ : Liège, Belgium
Funds raised : 3.7M€, comprise 1M€ non-dilutive funding
Management team : Emilie Dory CEO, Eric Rompen Founder, France Lambert Founder, Geoffrey Lecloux Founder

Technology

Development of superior bone graft substitute products for dental reconstruction surgery.

Wishbone has pioneered a breakthrough technology and innovative processes to develop a pipeline of new products for dental surgery building on its advanced bone graft material.

Business

Enhanced version of the current advanced xenograft product ready for clinical study
- Exceptional results from the pre-clinical study

USA distribution partnership
- Building a KOL network of clinician users

Milestones

2021: USA regulatory clearance
2022: USA Commercialisation, first patients and appointment of distribution partner
2023: Launch of a multicentric premarket clinical investigation in Belgium

Diagnostic & Tools Portfolio

Wallonie Entreprendre Life Sciences

In Our Portfolio

ABSCINT Precision Imaging
https://abscint.com/

Corporate

HQ : Liège, Belgium
Funds raised : 6M€
Management Team : Karine Clauwaert CEO, Martine Vandermarliere CTO, Gregory Thoorens COO, Philippe Wanwolleghem Chief Quality & Regulatory.

Business

ABSCINT is developing ABSCINT-HER2, a diagnostic product that visualizes all **cancer lesions expressing HER2** throughout the body.
This product can be used for different oncology indications:

1. **Screening** of **HER2-null and low metastatic breast and gastric cancer patients** to avoid undertreatment due to tumour heterogeneity (in case of a negative biopsy, no HER2-targeted therapy while the majority of lesions may HER2 based treatment show HER2 expression)
2. **Follow-up** of **HER2-positive and low metastatic breast and gastric cancer patients** under HER2-targeted therapy to monitor treatment efficacy (loss of HER2 expression under treatment should trigger treatment adaptation)

Technology

ABSCINT develops ***in vivo*** **imaging radiopharmaceutical diagnostics** also called positron emission tomography (**PET**) **tracers** based on **single-domain antibodies** (**sdAbs**).

sdAbs are small **antibody scaffolds**, which **bind to specific** surface proteins (**targets**) present on aberrant cells or cells of interest. To render the location of the targets **visible via PET imaging**, sdAbs are first **labeled with a radioisotope**, then administered (injected) to patients **90 minutes** before the PET image is taken.

Milestones

30/09/2024 : Start Phase 2b study (HERMIA trial)
04/11/2024 : Approval of Avance Récuperable HER2IVIM
22/10/2024 : First ABSCINT seminar at EANM presenting initial patient results of the HERMIA trial

Wallonie Entreprendre Life Sciences

In Our Portfolio

axithra

https://axithra.com/

Corporate

HQ : Ghent, Belgium
Funds raised : 11.5M€
Management Team : Leander Van Neste CEO & co-founder, Haolan Zhao CSO & co-founder, Jonathan Salmon CTO & co-founder, Nuria Teigell Beneitez System Architect & co-founder.

Business

Saving patients' lives and improving therapeutic outcomes through rapid therapeutic drug monitoring (TDM) at the point of need.
Providing clinically actionable results tailored to the individual patient, ensuring drug effectiveness and avoiding adverse drug reactions, leading to advantageous health economics.
Monitoring of ß-lactam antibiotics in the ICU as beachhead market and building out pipeline in the oncology sector.

Technology

Developing a rapid, point-of-need Raman spectroscopy-based platform for TDM, with fast readout, based on a true sample-in to result-out approach. The quick turnaround time allows for clinically actionable results at any time and any place, which is not readily possible with current technologies. Our label-free photonics solution can be implemented with a low total cost of ownership and allows for the direct measurement of the free, active fraction of drugs that enable physicians to manage patients more efficiently and effectively.

Milestones

2023 : Spun out of UGent and imec, establishing HQ
2023 : Completed €10M seed round
2024 : Received €1.5M VLAIO grant
2024/2025 : Established proof-of-concept (lab) prototype

In Our Portfolio

neuroClues
biomarkers in a blink
www.p3lab.com

Corporate

HQ : Ottignies-Louvain-La-Neuve, Belgium
Funds raised : 12M€ in equity and non-dilutive
Management Team : Antoine Pouppez CEO & Co-founder, Pierre Daya CTO & Co-founder.

Technology

NeuroCluesTM is a unique eye tracking solution integrating - a portable laboratory performing high quality measurements (800 fps) and analysis (with FPGA) within a controlled environment and in an ecological/comfortable patient position. - a frictionless software giving access to clinically relevant paradigms and providing science based biomarkers within minutes. - a series of services with an encyclopedia, a worldwide normalized cloud base dataset and SW updates & HW upgrades.

Business

Our Target Market Size by 2032 is 9 000 devices in leading to an ARR of 76M€ with 260 000 potential users (neurologists and vision specialists) worldwide leading to a Service Addressable Market of 1.5 bn€.
The total market size for neurological biomarkers in the clinical practice is 2 300 000 Clinical practitioners.

The clinical act is already reimbursable in most EU countries (FR-60€) and US (100$) leading to a positive business case for practitioners.

Main competitors are North-American based startups and scaleups with recent product launch relying on third party hardware solutions. In Europe, competition is setting up in the medical sector, demonstrating increased market readiness.

Milestones

Next R&D steps to reach:
EU : CE marking
US: 510K FDA submission
Next commercial steps to reach:
EU product launch
Used by KOL's in leading institutions
Corporate objectives:
Raise Serie A round

Wallonie Entreprendre Life Sciences

In Our Portfolio

SamanTree Medical SA

Corporate

HQ : Lausanne, Switzerland
Funds raised : 33M€
Management Team : Olivier Delporte CEO, Bertrand Grimmonpré CFO, Etienne Shaffer Founder & CTO

Technology

Histolog® Scanner: revolutionary microscopy device providing high-resolution, real-time imaging of fresh tissue at the point of care. Imaging the surface of excised human tissue specimens to visualize morphological microstructures and visualizing cancerous cells immediately. Targeting a wide range of cancer types, including breast, prostate, lung, and TURBT cancers. The Histolog® Scanner is poised to become a new standard in oncological care.

Business

Development and worldwide commercialization of capital equipment and disposables:

- US: direct commercialization with own sales force.
- EU & ROW: Mix between direct commercialization and distributors network.

Milestones

CE Mark 2019
FDA Clearance Sept 2024

Healthtech Portfolio

Wallonie Entreprendre Life Sciences

In Our Portfolio

MYOCENE SPORT TECHNOLOGY

www.myocene.com

Corporate

HQ : Liège, Belgium
Funds raised : 6.3M€
FTE : 9 employees
Management team : Jean-Yves Mignolet CEO

Technology

The Myocene device allow strength and conditioning coaches to measure the **muscle fatigue** of their athletes, in order to better plan and individualize the training sessions.
The device has been **scientifically validated** by one of the KOL in the field. A real-life **on-field usability validation** has been achieved by testing the device in top European clubs and world level athletes.

Business

Current R&D programs: Assessment of muscle fatigue due to exertion in healthy subjects, in all its components (peripheral and central)
Current market targets: Top-level sports clubs and athletes and university labs active in sports performance, both in EU and US

Milestones

2025 milestones:

- **FDA** clearance
- Cloud **deployment**
- US Market **launch**

In Our Portfolio

AXINESIS
ADVANCING REHABILITATION
www. axinesis.com

Corporate

HQ : Wavre, Belgium
Funds raised : 3M€
Management team : Pieter Van den Steen CEO and Julien Sapin Founder & CTO

Technology

Area of interest: offering Intensive Functional Neurorehabilitation across the continuum of care
Products description: Portfolio for upper-limb neurorehabilitation, with an end-effector robotic device (REAplan), a functional virtual reality workstation (REAtouch) and a functional virtual reality workstation for decentralized therapy (REAtouch Lite)
Milestones: all three products are CE marked and commercially available in Europe

Business

- Realizing full commercial coverage of Europe, Canada and Australia
- R&D axes: Telerehabilitation and cognitive decline

Milestones

- **2022 :** Break-even
- **2023-2025 :** commercialization in US, China & Russia and launch of telerehabilitation and cognitive decline applications

Wallonie Entreprendre Life Sciences

In Our Portfolio

www.gabismartcare.com

Corporate

HQ : Liège, Belgium
Funds raised : 4.8M€
FTE : 15 employees
Management team : Jonathan Baut CEO, Edouard Carton COO

Technology

Gabi SmartCare develops the very first Remote Patient Monitoring platform for **Pediatrics** (0 to 12 years, including premature babies). By monitoring the child's main vital signs and interpreting them with AI (Artificial Intelligence), our solution allows to reduce readmissions, Hospital length of stay and preventable ER visits. The solution consists of a proprietary hardware and software components as well as a medical support service: the Gabi Band, the Gabi Monitor, and the Gabi Analytics.

Business

- **GEN 2** finalised and medically validated, **FDA Pre-sub** done, ongoing **clinical trials** (US and Belgium)
- Validated business model with a **2-step market penetration:** Research applications with more than 30 paying hospital customers in 1 year of sales, and now launching Clinical Applications.
- Market geography: **US**
- Top-notched **scientific and strategic board**

Milestones

Next years' main milestones:

- **Medical certification** in the US and EU by Q4 2023
- **Sold to 31 paying hospital customers** for research applications in 2023
- **Clinical Application Pilots launched** with key hospitals by in 2024

Service Portfolio

Wallonie Entreprendre Life Sciences

In Our Portfolio

www.aseptictech.com

Corporate

HQ : Gembloux, Belgium
Funds raised : 35M€
Management team : Patrick Balériaux CEO

Technologies

- Aseptic filling technology (AT-Closed Vial® Technology, made of ready-to fill vials and related filling equipment)
- Aseptic fluid path: manufacturing of filling kits and aseptic liquid transfer systems (AT-Port™)
- Custom injection-molding and clean manufacturing of pharmaceutical devices.

Business

Aseptic Technologies develops, manufactures and commercializes equipment and devices for biopharmaceutical aseptic processes, with a special focus on the Fill & Finish of injectable drugs, including cell and gene therapy products.

As member of the Swiss group SKAN, Aseptic Technologies leverage the technological excellence of SKAN in the field of isolator technology to provide integrated solutions for fill & finish projects, globally.

Furthermore, Aseptic Technologies shares decades of expertise in plastic injection molding and manufacturing of assemblies in clean conditions.

Milestones

First drug approved in AT-Closed Vial® :
- in Europe (2019)
- in Japan (2021)
- in US and UK (2022)
- in Canada and Australia (2023)

500th filling equipment installed (2023)
Takes the majority in Plast4Life (2024)

In Our Portfolio

LiveDrop

www.Livedrop-bio.com

Corporate

HQ : Liège, Belgium
Funds raised : 1.4M€ + 0.9M€ non-dilutive
FTE : 6 employees
Management team : Stéphanie van Loo CEO & CTO, Geoffrey Holsbeek CBDO, Yacine Bounab CSO

Technology

ModaFlow is an all-in-one integrated instrument based on droplet microfluidics for high-throughput single-cell screening and sorting.
ModaFlow is particularly adapted to single-cell analysis and sorting of fragile cells. Moreover, it allows unique secretome-based single-cell sorting, e.g. for the selection of monoclonal antibodies producing cells.

Business

Current market targets : institutional and private R&D laboratories, R&D department of biotech and biopharma companies active in the field of immunology, immuno-oncology, immunotherapy , bioproduction, microbiology, cell & gene therapy, regenerative medicine.

Milestones

Commercialisation of the first ModaFlow in 2023.

In Our Portfolio

QUALITY ASSISTANCE
Contract Research Organisation
www.quality-assistance.com

Corporate

HQ : Thuin, Belgium
FTE : 234 employees
Management team : Nathalie Draux CEO, Nicolas Theys COO
Revenues 2023 : 30M€

Technology

Mass Spectrometry
Bioassays
Protein Characterisation
Molecular Biology
Chromatography
Bioanalysis (PK/TK/Immuno)
Immunoassays
Microbiology

Business

All the analytical services
required by EMA and FDA regulations for the development and marketing of innovative human medicinal products

- New Chemical Entities
  - Peptides
  - Oligonucleotides
- Biologics
  - Antibody-Drug Conjugates
  - Monoclonal antibodies
  - Proteins
- Nanomedicine Products
- Vaccines
- mRNA
- Cell and Gene Therapies

Milestones

2025 : 4th facility expansion phase – **MITOSE** – reaching 12 000 m^2
3 facility expansion
phases, reaching 6000m^2

GMP certified since **1984**
GLP certified since **2004**
Speed up people's access to **more than 600 innovative drugs**

FDA inspected in **2019, 2014, 2010, 2003**

Wallonie Entreprendre Life Sciences

In Our Portfolio

UniD Manufacturing
Your CDMO for Sustained Drug Delivery Solutions

www.unid-manufacturing.com

Corporate

HQ : Liège, Belgium
FTE : 45 employees
Management team : Mélanie Mestdagt CEO, Marc Foidart Executive Chairman

Business

UniD Manufacturing is a global CDMO fully dedicated to sustained drug delivery solutions.

From your ideas to the market, we are the partner who supports and endorses you through every stage of your project based on bioresorbable, biodegradable and non-biodegradable polymers, for medical devices and drugs.

We are an excellence center with unique tailor-made in-house equipment in two GMP approved environment, and talented experts to develop and manufacture your polymeric-based formulations and your controlled release products, in all dimensions.

Technology

POLYMERIC FORMULATIONS
- Biodegradable
- Non-biodegradable
- Resorbable
- Medical devices & drugs

CONTROLLED RELEASE
MICRO & MACRO TECHNOLOGY

Services

- R&D and preclinical
- Clinical phases
- Commercial

Products

- Implants & inserts
- Medical devices & drugs

Your CDMO for Long-Acting Formulations

Wallonie Entreprendre Life Sciences

In Our Portfolio

Univercells
Biologics for all
www. univercells.com

Corporate

HQ : Charleroi, Belgium
Management team : Hugues Bultot CEO, José Castillo CTO, Tim Carlson President, Kate Antrobus CBO, Vincent Vanderborght CFO, David Louvet COO & CHRO

Affiliate CEO's : Cédric Volanti (Exothera); José Castillo (Quantoom Biosciences and Univercells France); Hala Audi (Unizima); David Louvet (RLM Consulting and Univercells International)

Technology

Exothera : a GMP-certified CDMO offering a complete range of services for viral vectors, RNA therapeutics, and vaccines.

Quantoom Biosciences: re-inventors of mRNA production. A technology company dedicated to advancing RNA manufacturing process applications.

Business

Univercells is a global group of biotech innovators rooted in Belgium, driven by one purpose: to transform how biotech drugs are made so everyone, everywhere, can get them. Through cutting-edge bioprocessing and technology, they create transformative processes and platforms across drug discovery, development, and delivery. Their focus is accessibility, affordability, and sustainability, to eliminate barriers for drug developers. Collaborating with the biotech and pharmaceutical industries, Univercells is paving the way for new vaccines and therapies targeting cancer, infectious diseases, and animal health.

Milestones

2024 : 2 collaborations with Serum Institute of India (SII) on personalized cancer vaccines and pandemic response (avian flu). The collaboration with Oxford University can redefine how RNA therapies are developed and brought to market in the UK, benefiting patients everywhere.

Ready for (ad)venture capital funding?

WE are on a mission to turn the Walloon region into a leading biotech hub in Europe.

WE invest in tomorrow's treatments to transform lives.

LinkedIn
@WE Life Sciences

Wallonie Entreprendre Life Sciences